Member Info for Energyshares

Could Avacta’s TNBC partner be announced or even DX purchaser made public.

JANUARY 13-16, 2025 | SAN FRANCISCO, CALIFORNIA

43rd Annual J.P. Morgan

Healthcare Conference

GLA keep hold of your golden tickets…..

WAG

“The debt you accrued to acquire a business is your debt and if placed on the company being sold will simply be taken into account and price received adjusted accordingly. Plus I don’t expect the deal value to exceed the debt.”

We will see

Should find out very soon

Most of the HCI loan was taken out to purchase Launch & Coris.

So I would hope this portion of loan is added to the sale price or transferred to new owners once that the division is sold.

A lot of guess work from LTH’s on sale price.

No company would borrow money to purchase loss making companies make them profitable then sell them but keep the debt.

I expect HCI loan to be cleared in sale of DX.

Now five indications in phase 1b.

We will find out soon the identity of the Avacta BP sugar daddy.

BP will know all about the FDA's "Everlasting Gobstopper" Policy.

So it is noteworthy that under a little-known FDA policy, ODD, once granted, never expires. And it isn't limited to the drug product that was originally designated. Instead, it can be used over and over again to transfer ODD status to new drugs in the original sponsor’s product line.

https://www.lassmanfdalaw.com/orphan-drug-designation-the-gift-that-keeps-on-giving/

Avacta won’t have any shortage of patients in 1b or phase 2

MD Anderson’s Nellie B. Connally Breast Center is named for a fierce breast cancer advocate and former First Lady of Texas. With Nellie in mind, we strive to treat each breast cancer patient with personalized attention, the best diagnosis and treatment options, and follow-up care to maximize your life after cancer.

We are one of the largest breast cancer centers in the United States, treating 40,000 patients a year. This gives us a level of experience that is second to none. Our team of experts uses this knowledge to create highly specialized treatment plans for all types and stages of breast cancer.

MD Anderson’s approach to breast cancer is more than just treatment. The Breast Center offers genetic testing and counseling for women with a family history of breast cancer. Your care team also includes skilled plastic surgeons that can make you look and feel normal again with the latest breast reconstruction procedures.

Choosing the right hospital may be the most important decision you make as a triple-negative breast cancer patient. At MD Anderson, you’ll get treatment from one of the nation’s top-ranked cancer centers.

The surgeons, radiation oncologists and medical oncologists with the Nellie B. Connally Breast Center focus exclusively on curing breast cancer, extending the life of breast cancer patients and maximizing their quality of life.

Among them are many physicians who specialize in treating TNBC. Each doctor brings their skills to our multidisciplinary teams, where they work together to develop treatment plans that address the unique nature of each TNBC case and patient.

If a patient receives both chemotherapy and immunotherapy before surgery, the tumor’s response must be monitored closely. At MD Anderson, our dedicated breast imaging team tracks these tumors with state-of-the-art imaging that provides accurate pictures of the tumor throughout treatment.

As a top-ranked cancer center, we also have one of country’s the largest clinical trials program for triple-negative breast cancer. This includes studies of new treatments and treatment combinations, including clinical trials that are not available anywhere else.

https://www.mdanderson.org/cancer-types/breast-cancer/triple-negative-breast-cancer.html#

“ Can you be cured with this new treatment in the United States, in Europe, and in other parts of the world?

Once we prove that the combination of the medication with the Avacta technique works, of course it is approved and you can be cured everywhere in the world.”

Gilead Sciences, Inc who makes Trodelvy and Merck who makes Keytruda must be monitoring the Ava6000 TNBC trial.

Both these drugs give off horrendous side effects.

Avacta know they have a drug that can become the standard of care for TNBC,last summer CC said it would be too expensive to pivot into Breast cancer, now they are in a P1b trial for TNBC where has the money come from ?

Merck ,Gilead or another BP we will find out soon….

“The reality is that there is an urgent need for new and better therapies for metastatic TNBC.”

https://tnbcfoundation.org/living-with-tnbc/living-with-metastatic-tnbc

GSA asked Avacta for a RNS so they can get out of their short.

Thanks CC

Ely Lilly venture arm could be a source for funding for Avacta.

They know all about Pre/Cision

Let's Grow Together

We have a proven legacy of successfully funding, developing and accelerating innovation to address unmet needs. In fact, collaboration and partnerships are at the center of our origin.

Through our Corporate Business Development team, we offer strategic collaborations and partnerships. Our interests are primarily within our core therapeutic areas: Diabetes and related complications, Immunology, Neuroscience, and Oncology. We are also interested in platform technologies.

https://www.lilly.com/partners

Below is a article on all the

US health care venture capital firms, scroll to bottom to see list.

Once DX is sold Avacta could be a target for these funds.

https://www.excedr.com/blog/top-vc-firms-for-biotech

What will LTH’s receive for Christmas from Avacta.

The silence is spooking share holders.

Come on CC give an update on the trial or even that Simon Bennett still works for Avacta and is still very busy.

If the RNS machine is bust get it fixed.

Should Avacta cherry pick some AVA6000 data to move SP.

https://x.com/jacobplieth/status/1863955159748837682?s=46

Launch posted full accounts on 20th Oct 2022 a month later Avacta buyout announced.

Avacta half year accounts end of December, so would it be possible DX sale announced after early Jan 25.

What is the implications selling before half year accounts published ?

Just a thought….

Why all the stress over the CFO.

Give them time,new CFO could be serving their notice from their employer now.

We have two excellent board members who can offer guidance if needed before CFO appointment.

Paul Fry

Non Executive Director

Paul was appointed as a Non- executive Director in February 2020. Paul has extensive financial experience across several industries including biotech, pharmaceutical and telecommunications. Paul was recently Chief Financial Officer of Argenta, a global CRO and CDMO specialising in animal health. Prior to this he was Chief Financial Officer of Vectura Group Ltd, an industry-leading inhaled drug delivery specialist which up until 2021 was listed on the FTSE Main Market.

Paul was also Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor technology. Paul has also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GlaxoSmithKline (‘GSK’), where he held several senior roles including Head of Global Finance Services and Chief Financial Officer for GSK’s Italian pharmaceutical business.

Paul holds a degree from Oxford University and is a member of the Chartered Institute of Management Accounts.

Darlene Deptula-Hicks

Non Executive Director

Ms. Deptula-Hicks is the interim CFO at Normunity, and prior to that served as CFO of F-star Therapeutics (NASDAQ:FSTX), which she took public in 2020 and successfully sold in 2023. Previously, she held the role of CFO at Northern Biologics and T2 Biosystems (NASDAQ:TTOO). She also served as SVP and CFO of Pieris Pharmaceuticals (NASDAQ:PIRS) which she also took public. Ms. Deptula-Hicks currently sits on the Board of Directors of Abcuro and Aerami Therapeutics, providing strategic financial and business direction.  Ms. Deptula-Hicks received her M.B.A. from Rivier University and B.S. in Accounting from Southern New Hampshire University.

AVA6000 was in this awards last year and never won…

Could be this year

I hope it a nice surprise.

Confirmation that P1b has started in all three indications,

and the name of the BP who is funding TNBC arm.

Now that would be third party validation and a very nice Christmas.

Sheffield property developers rubbing their hands, a few churches going cheap soon.

CJ

If that is the case why start paying loan off in cash.

If you pay loan you save 25 million shares per year been dumped onto the market. 3 years left ??

So next raise SP would have a chance to recover

The reckless twins AS & TG

acquired Launch Diagnostics Holdings Limited for an upfront cash consideration of £24 million then acquired Coris Bioconcept SRL for an upfront cash consideration of £7.4 million.

That’s £31.4 million on two loss making companies they then said they were still looking for other targets.

The rest of the HCI loan has been used as cash flow.

Now that those companies are now cash generative and shareholders have took the pain from these awful acquisitions, I’m expecting at least £31.4 million back for them now they are making money.

With CC saying they had a few bidders it’s not a fire sale,so £31.4 million could be coming back and with outstanding loan at £30.6 million that has got to be one of the worst corporate decisions in history,

A.Smith if your reading this your legacy could have been so different if you would have just listened to the board you had around you instead of your fantasy pursuit of affimers.

This loan has been pointless…

Onwards and upwards once this awful loan is paid back.

GLA

AI Overview

CanSEEK is a technology developed by POINT Biopharma that Eli Lilly acquired in order to expand its oncology capabilities:

Purpose

CanSEEK aims to reduce radiopharmaceutical toxicity by only activating a radiopharmaceutical's targeting moiety after it has encountered FAP-α in the tumor microenvironment.

Drug candidates

Eli Lilly is developing drug candidates based on CanSEEK technology for the treatment of:

PNT-2001: A drug candidate for the treatment of biochemically recurrent and metastatic castration-resistant prostate cancer (mCRPC) and recurrent hormone-sensitive prostate cancer.

Lutetium Lu 177 dotatate: A drug candidate for neuroendocrine tumors that targets somatostatin receptor 2 (SSTR2).

I found this on another link saying LU 177 is in phase 3.

If true and these drugs are using CanSEEK,

Avacta are in for some royalties in the next few years why isn’t this being reported by Avacta and their brokers.

Lutetium Lu 177 dotatate is under clinical development by Eli Lilly and Co and currently in Phase III for Neuroendocrine Tumors. According to GlobalData, Phase III drugs for Neuroendocrine Tumors have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lutetium Lu 177 dotatate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

https://www.pharmaceutical-technology.com/data-insights/lutetium-lu-177-dotatate-eli-lilly-and-co-neuroendocrine-tumors-likelihood-of-approval/